StockNews.AI
AMD
StockNews.AI
36 days

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape

1. The wet AMD market is growing due to an aging population. 2. Emerging therapies like gene therapy and AI diagnostics are expected to thrive. 3. High treatment costs and access issues may hinder market growth. 4. Companies are innovating to improve effectiveness and reduce costs. 5. Major competitors include Regeneron and Adverum Biotechnologies.

9m saved
Insight
Article

FAQ

Why Neutral?

While the wet AMD market growth is notable, AMD's direct involvement is unclear. Historical data shows AMD's stock responding variably to healthcare news depending on direct relevance.

How important is it?

The insights about technological advancements in diagnostics and treatment options could benefit AMD indirectly if they enter this market. However, without AMD-specific developments mentioned, the impact remains moderate.

Why Long Term?

If AMD extends their technology into health-related diagnostics or treatments, this could positively influence. However, no immediate plans or connections are mentioned.

Related Companies

REGNADVMPFENVDAINTC
Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Wet Age-Related Macular Degeneration (Wet AMD) Market - A Global and Regional Analysis: Focus on Treatment Type, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global wet age-related macular degeneration market is experiencing robust growth, driven by an aging population, increasing awareness about the condition, and advancements in treatment options. Wet age-related macular degeneration represents a major challenge for healthcare systems globally, as it significantly impacts the quality of life and imposes a high burden on individuals and economies. As the wet age-related macular degeneration market continues to evolve, emerging trends such as the development of long-acting therapies, the integration of advanced diagnostic technologies like artificial intelligence (AI) for early detection, and the increasing focus on personalized medicine will shape its future trajectory. The growing demand for more affordable, effective, and accessible wet age-related macular degeneration treatments, particularly in underserved regions with limited healthcare infrastructure, will create significant opportunities for market expansion. The global wet age-related macular degeneration market is on track for continued growth, driven by the aging population, increasing awareness of wet age-related macular degeneration, and the development of more effective and comfortable solutions. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for wet age-related macular degeneration solutions rises, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems alike, improving the quality of life for people living with incontinence. Key therapeutic approaches for wet age-related macular degeneration include anti-VEGF (vascular endothelial growth factor) therapies, photodynamic therapy, and laser surgeries, with the anti-VEGF drugs holding the largest market share due to their proven efficacy in halting or slowing disease progression. Furthermore, emerging treatments, including cell and gene therapy and stem cell therapy, are gaining attention as potential future solutions.The most significant driver for the wet age-related macular degeneration market is the aging global population. As people live longer, the incidence of age-related eye conditions, including wet age-related macular degeneration, increases. Age-related macular degeneration is most common in individuals aged 65 and older, and as the world's elderly population continues to grow, particularly in developed nations, the number of wet age-related macular degeneration cases rises. The UN projects that the number of people aged 80 and older will increase from 143 million in 2019 to 426 million by 2050, leading to a larger patient pool for wet age-related macular degeneration treatments.Technologies such as optical coherence tomography (OCT) and fundus photography have greatly enhanced the ability to detect wet age-related macular degeneration at an early stage. Early diagnosis allows for timely intervention, helping to slow disease progression and improve patient outcomes. The adoption of advanced diagnostic tools in clinics and hospitals is driving market growth by enabling healthcare providers to identify patients who would benefit from anti-VEGF therapies or other treatments.The wet age-related macular degeneration market is indeed growing due to increasing awareness, technological advances in treatments, and an aging global population. However, the combination of high treatment costs, side effects, limited access to care, and the ongoing challenge of offering curative treatments are significant factors restricting the market's potential. Companies in the sector need to focus on reducing the cost of treatment, improving patient adherence, and advancing research to provide long-term and potentially curative therapies for Wet AMD. Addressing these challenges will be key to unlocking the market's full growth potential.Some of the major players in the global wet age-related macular degeneration market, such as Regeneron Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, and Adverum Biotechnologies Inc., are continuously innovating to improve the effectiveness and comfort of wet age-related macular degeneration products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of wet age-related macular degeneration while enhancing their market positions globally.The competitive landscape of the global wet age-related macular degeneration market is diverse, with numerous players across different regions offering a wide range of products. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the wet age-related macular degeneration market will continue to evolve, fostering new opportunities for both established and emerging companies.Key Topics Covered:1. Global Wet Age-Related Macular Degeneration Market: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology of Wet Age-Related Macular Degeneration1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Wet Age-Related Macular Degeneration Market, by Treatment Type, $Million, 2023-20352.1 Anti-VEGF Therapies2.2 Gene Therapy2.3 Others3. Global Wet Age-Related Macular Degeneration Market, by Region, $Million, 2023-20353.1 North America3.1.1 Key Findings3.1.2 Market Dynamics3.1.3 Market Sizing and Forecast3.1.3.1 North America Wet Age-Related Macular Degeneration Market, by Country3.1.3.1.1 U.S.3.2 Europe3.2.1 Key Findings3.2.2 Market Dynamics3.2.3 Market Sizing and Forecast3.2.3.1 Europe Wet Age-Related Macular Degeneration Market, by Country3.2.3.1.1 Germany3.2.3.1.2 U.K.3.2.3.1.3 France3.2.3.1.4 Italy3.2.3.1.5 Spain3.3 Asia Pacific3.3.1 Key Findings3.3.2 Market Dynamics3.3.3 Market Sizing and Forecast3.3.3.1 Asia Pacific Wet Age-Related Macular Degeneration Market, by Country3.3.3.1.1 Japan4. Global Wet Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles4.1 Key Strategies and Developments by Company4.1.1 Funding Activities4.1.2 Mergers and Acquisitions4.1.3 Regulatory Approvals4.1.4 Partnerships, Collaborations and Business Expansions4.2 Company Profiles4.2.1 Overview4.2.2 Top Products / Product Portfolio4.2.3 Target Customers/End-Users4.2.4 Key Personnel4.2.5 Analyst View Regeneron Pharmaceuticals IncOphthotech CorporationAdverum Biotechnologies IncApellis Pharmeceuticals IncKubota Pharmaceutical Holdings Co. Ltd.Pfizer Inc.Novartis AG For more information about this report visit https://www.researchandmarkets.com/r/g2pe5i About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News